Attached files

file filename
10-Q - FORM 10-Q - ACHILLION PHARMACEUTICALS INCd230843d10q.htm
EX-31.1 - SECTION 302 CEO CERTIFICATION - ACHILLION PHARMACEUTICALS INCd230843dex311.htm
EX-32.2 - SECTION 906 CFO CERTIFICATION - ACHILLION PHARMACEUTICALS INCd230843dex322.htm
EX-31.2 - SECTION 302 CFO CERTIFICATION - ACHILLION PHARMACEUTICALS INCd230843dex312.htm
EX-32.1 - SECTION 906 CEO CERTIFICATION - ACHILLION PHARMACEUTICALS INCd230843dex321.htm
EXCEL - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCFinancial_Report.xls
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR3.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR4.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR7.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR5.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR6.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR1.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR9.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR8.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR2.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR16.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR12.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR15.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR14.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR11.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR10.htm
XML - IDEA: XBRL DOCUMENT - ACHILLION PHARMACEUTICALS INCR17.htm
v2.3.0.15
Accrued Expenses
9 Months Ended
Sep. 30, 2011
Accrued Expenses [Abstract] 
Accrued Expenses

8. Accrued Expenses

Accrued expenses consist of the following:

 

     September 30, 2011      December 31, 2010  

Accrued compensation

   $ 1,479       $ 978   

Accrued research and development expenses

     2,062         676   

Accrued professional fees

     300         317   

Other accrued expenses

     251         90   
  

 

 

    

 

 

 

Total

   $ 4,092       $ 2,061   
  

 

 

    

 

 

 

 

Accrued research and development expenses are comprised of amounts owed to third-party contract research organizations or "CROs", clinical investigators, laboratories and data managers for research and development work performed on behalf of the Company.